



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/579,078	06/16/2007	Herve Groux	0733-1001	1413
466	7590	02/08/2010		
YOUNG & THOMPSON			EXAMINER	
209 Madison Street			JUEDES, AMY E	
Suite 500				
Alexandria, VA 22314			ART UNIT	PAPER NUMBER
			1644	
NOTIFICATION DATE	DELIVERY MODE			
02/08/2010	ELECTRONIC			

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

DocketingDept@young-thompson.com

<b>Office Action Summary</b>	<b>Application No.</b> 10/579,078	<b>Applicant(s)</b> GROUX ET AL.
	<b>Examiner</b> AMY E. JUEDES	<b>Art Unit</b> 1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED. (35 U.S.C. § 133).

Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 30 November 2009.

2a) This action is FINAL.      2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1-44 is/are pending in the application.

4a) Of the above claim(s) 1-28,33-36,42 and 43 is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 29-32,37-41 and 44 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statements (PTO/SB/06)  
Paper No(s)/Mail Date 11/17/06, 5/11/06

4) Interview Summary (PTO-413)  
Paper No(s)/Mail Date: \_\_\_\_\_

5) Notice of Informal Patent Application

6) Other: \_\_\_\_\_

**DETAILED ACTION**

1. Applicant's election of the species of formulation comprising a lipopeptide and further comprising a peptide/polypeptide, in the reply filed on 11/30/09, is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

Claims 1-28 and 42-43 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention. Claims 33-36 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected species.

Claims 29-32, 37-41, and 44 read on the elected invention and are being acted upon.

2. Claims 29-32 and 37-41 are objected to as being improper dependent claims. A proper dependent claim shall not conceivably be infringed by anything which would not also infringe the base claim. In the instant case, the claims are drawn to formulations comprising the lipopeptides of claim 1 (a method claim). However, it is conceivable that the product claims can be infringed without infringing the method of claim 1, since the peptides might be used for a different purpose than recited in the method of claim 1.

See MPEP § 608.01(n).

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:  
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 31-32 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 31 specifies that the pharmaceutical formulation further comprises, as a combined preparation, the peptide antigen or a polypeptide comprising said peptide, to

be administered prior to the topical administration of the lipopeptide. The recitation of a "combined" preparation appears to indicate that the formulation comprises a lipopeptide and a peptide in a single composition. However, claim 29 is already direct to a single composition comprising both a peptide and a lipopeptide. Furthermore, the claims also specify that the formulation is to be administered subcutaneously prior to the topical administration of the lipopeptide composition. Thus, it is not clear if the "combined preparation" might refer to two separate formulations, one comprising a lipopeptide for topical administration, and one comprising a peptide/polypeptide for subcutaneous administration. Therefore, the metes and bounds of the claims cannot be established. For the purposes of examination, claim 31 is being interpreted as single formulation comprising both a lipopeptide and a peptide/polypeptide.

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:  
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.
5. Claims 37-40 and 44 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for:

A pharmaceutical formulation or cosmetic formulation comprising a lipopeptide and a topical/cosmetic carrier,

does not reasonably provide enablement for:

A pharmaceutical/cosmetic formulation comprising a lipopeptide and a topical/cosmetic carrier for treating or preventing a skin disease, diseases of the mucosa, chronic inflammatory disorders and autoimmune pathological disorders.

The specification disclosure is insufficient to enable one skilled in the art to practice the invention as claimed without an undue amount of experimentation. Undue experimentation must be considered in light of factors including: the breadth of the claims, the nature of the invention, the state of the prior art, the level of one of ordinary

skill in the art, the level of predictability of the art, the amount of direction provided by the inventor, the existence of working examples, and the quantity of experimentation needed to make or use the invention, *in re Wands*, 858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988).

"The amount of guidance or direction needed to enable the invention is inversely related to the amount of knowledge in the state of the art as well as the predictability in the art." *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). The "amount of guidance or direction" refers to that information in the application, as originally filed, that teaches exactly how to make or use the invention. The more that is known in the prior art about the nature of the invention, how to make, and how to use the invention, and the more predictable the art is, the less information needs to be explicitly stated in the specification. In contrast, if little is known in the prior art about the nature of the invention and the art is unpredictable, the specification would need more detail as to how to make and use the invention in order to be enabling (MPEP 2164.03)" The MPEP further states that physiological activity can be considered inherently unpredictable.

The instant claims are drawn to a pharmaceutical composition comprising a lipopeptide, wherein said composition is effective for treating or preventing a broad range of diseases, including inflammatory autoimmune diseases, cancer, and infection. As an initial matter, it is noted that the term "prevention" given its broadest reasonable interpretation, encompasses a complete prevention such that no signs or symptoms of disease ever develop. Additionally, in the case of infection, the instant claims encompass a complete prevention of infection such that no cells or tissue are ever infected with a pathogen. The complete "prevention" of disease or infection, as is encompassed by the instant claims, is highly unpredictable. Furthermore, the instant claims encompass using the claimed compositions to treat conditions with widely different etiologies and pathological mechanisms. For example, treatment of autoimmune disease involves suppressing a pathogenic immune response, while treatment of infection or cancer involves inducing a protective immune response. The ability of a single treatment to be effective for such widely divergent diseases is highly unpredictable. Furthermore, lipopeptides are known to have an inflammatory adjuvant

effect, enhancing the immune response to peptide antigens (see Le Gal et al.). Thus, while it might be possible to use a viral or bacterial peptide conjugated to a lipid to treat infection, or to use a tumor peptide conjugated to a lipid to treat cancer, the instant claims are not limited in this regard. Furthermore, the instant claims encompass using the claimed lipopeptides to treat autoimmune inflammatory disease, which would be highly unpredictable given the immune stimulating effect of lipopeptides.

Thus, given the breadth of the claims and the unpredictability of the art, the instant specification must provide a sufficient disclosure to enable one of skill in the art to use the compositions as broadly claimed. The instant specification demonstrates that a tumor peptide lipopeptide conjugate is effective in inducing an antigen specific TH1 immune response. However, the claims are not limited to a lipopeptide tumor peptide conjugate for treating cancer, but broadly encompass treating or preventing a myriad of diseases with any lipopeptide. The instant specification further demonstrates that a lipopeptide-OVA peptide conjugate is effective at stimulating adoptively transferred OVA specific regulatory T cells *in vivo*. However, no evidence is provided that a lipopeptide composition by itself (i.e. in the absence of co-transfer of regulatory T cells) is effective for treating or preventing autoimmune disease, as claimed. Thus, given the breadth of the claims, the unpredictability of the art, and the lack of guidance provided by the instant specification, it would require undue experimentation to use the lipopeptide compositions, as broadly claimed.

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

- (a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.
- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

7. Claims 29-32, 37-41, and 44 are rejected under 35 U.S.C. 102(a) as being anticipated by Foussat et al., available online Nov. 7, 2003 (of record).

Foussat et al. teach a lipopeptide composition comprising an antigen peptide specific for a T cell population, wherein said peptide is coupled covalently to a lipid. Foussat et al. also teach topical administration of the lipopeptide in an olive oil solution (i.e. a pharmaceutically topical/cosmetic acceptable carrier, see page 5020 in particular). Additionally, Foussat et al. teach that the lipopeptide activates Tr1 cells. Additionally, said composition can be considered a "combined" preparation comprising the peptide. Additionally, said lipopeptide would inherently be capable of activating CD3+CD4+CD18brightCD49b+ cells, and treating inflammatory diseases or other diseases of the skin/mucosa, since it is the same as the composition of the instant claims. Additionally, the limitations of claim 31 wherein a prior immunization is made subcutaneously refers to an intended use of the claimed composition, and does not render the instant claims patentable in the absence of a structural difference.

Thus, the reference clearly anticipates the invention.

8. Claims 29-32, 37-41, and 44 are rejected under 35 U.S.C. 102(b) as being anticipated by Le Gal et al., 2002.

Le Gal et al. teach a pharmaceutical composition comprising a lipopeptide and IFA (i.e. a water-in oil emulsion, see page 222and 224 in particular). The instant specification on pages 6 and 16 teaches that pharmaceutically topical acceptable carriers or cosmetically acceptable carriers include water-in-oil emulsions. Thus, the IFA of Le Gal et al. can be considered a pharmaceutically topical acceptable carrier or a cosmetically acceptable carrier, as recited in the instant claims. Le Gal et al. teach that the lipopeptide comprises peptides specific for a T cell population covalently coupled to a lipid group (i.e. a radical, see page 221-222, in particular). Additionally, said composition can be considered a "combined" preparation comprising the peptide. Le Gal et al. teach that the lipopeptide is capable of stimulating both CTL and T helper cells (i.e. CD8+ or CD4+ T cells, see page 221 and 224, in particular). Le Gal et al. teach that the lipopeptide compositions can be used as a melanoma vaccine (i.e. to treat melanoma). Furthermore, said lipopeptide would inherently be capable of activating CD3+CD4+CD18brightCD49b+ cells, and treating inflammatory diseases or diseases of

the mucosa, since it is the same as the composition of the instant claims. Additionally, the limitations of claims 30-31 wherein composition is to be administered topically/subcutaneously/intraperitoneally refers to an intended use of the claimed composition, and does not render the instant claims patentable in the absence of a structural difference.

Thus, the reference clearly anticipates the invention.

9. No claim is allowed.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy E. Juedes whose telephone number is 571-272-4471. The examiner can normally be reached on 7am to 3:30pm, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Art Unit: 1644

Amy E. Juedes

Patent Examiner

Technology Center 1600

/Amy E. Juedes/

Primary Examiner, Art Unit 1644